Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)

被引：0
|
作者：
Schuchardt, C. [1 ]
Kulkarni, H. R. [1 ]
Wiessalla, S. [1 ]
Shahinfar, M. [1 ]
Shafaei, S. [1 ]
Kropf, S. [2 ]
Wester, H. J. [3 ,4 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka GmbH, THERANOST Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Scintomics GmbH, Fuerstenfeldbruck, Germany
[3] Tech Univ Munich, Fac Chem, D-80290 Munich, Germany
[4] Tech Univ Munich, Fac Med, D-80290 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP291
引用
收藏
页码：S224 / S225
页数：2
相关论文
共 50 条
  • [1] Serial Dosimetry in Peptide Receptor Radionuclide Therapy using Lu-177 DOTATATE or Lu-177 DOTATOC in the same Patient
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [2] Lu-177 HA-DOTATATE for Peptide Receptor Radionuclide Therapy (PRRT): First Results in Patients Concerning Biodistribution, Normal Organ and Tumor Dosimetry
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S224
  • [3] LU-177 DOTATATE THERAPY IN PATIENTS WITH NETS
    Hosking, E.
    McKay, E.
    Browne, E.
    Thomas, D.
    Liauw, W.
    Morris, D.
    Chu, F.
    Hayes, A.
    Butler, P.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 18 - 18
  • [4] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Josephine Graf
    Ulrich-Frank Pape
    Henning Jann
    Timm Denecke
    Ruza Arsenic
    Winfried Brenner
    Marianne Pavel
    Vikas Prasad
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 881 - 894
  • [5] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Graf, Josephine
    Pape, Ulrich-Frank
    Jann, Henning
    Denecke, Timm
    Arsenic, Ruza
    Brenner, Winfried
    Pavel, Marianne
    Prasad, Vikas
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 881 - 894
  • [6] Establishing a Lu-177 Dotatate Therapy Program
    Snyder, W.
    Harpool, K.
    Swanson, J. W.
    Schantz, P.
    Phan, A.
    Dick, J. S.
    Cavanaugh, S. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E499 - E500
  • [7] Patient release after Lu-177 DOTATATE and Lu-177 PSMA 617 therapies
    Mair, C.
    Warwitz, B.
    Buxbaum, S.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S454 - S454
  • [8] A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)
    Ross, Erin
    Ram, Lydia
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [9] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
    Kamaleshwaran, K.
    Sudhakar, N.
    Paulvannan, S.
    Vysakh, M.
    Shinto, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
  • [10] Peptide receptor radionuclide therapy using somatostatin receptor antagonists: first results of biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC
    Schuchardt, Christiane
    Kulkarni, Harshad
    Singh, Aviral
    Mueller, Dirk
    Fani, Melpomeni
    Maecke, Helmut
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
12345